Hypothesis

Progressive loss of calbindin‑D28k in basal forebrain cholinergic (BFCN) neurons triggers a compensatory upregulation of alternative calcium‑binding proteins (e.g., parvalbumin, S100B). This heightened buffering demand consumes ATP, impairs chaperone‑mediated refolding, and pushes the proteostasis network toward sequestering calcium‑oxidized, supersaturated proteins into insoluble aggregates. Thus, aggregation is not a random byproduct but a metabolically costly protective response that preserves soluble monomer function until the buffering system fails.

Mechanistic Rationale

1. Calbindin depletion creates a calcium‑handling gap – Aging BFCNs lose calbindin yet show 50‑100 % increased rapid calcium buffering (2). The gap is filled by inducible calcium‑binding proteins whose expression is energetically expensive.
2. ATP diversion reduces chaperone capacity – Elevated calcium buffering raises cytosolic ATP consumption for Ca²⁺‑ATPase pumps, limiting ATP available to Hsp70/Hsp90 systems. Reduced chaperone activity favors accumulation of misfolded, oxidation‑prone proteins.
3. Aggregation as a sequestration solution – When soluble monomers become depleted, the cell directs damaged proteins into dense, thermodynamically stable aggregates (1). These deposits act as inert sinks, preventing diffusion of toxic species while preserving the remaining soluble pool.
4. Failure point – Sustained proteostatic stress overwhelms the compensatory buffering system; aggregates then exert toxicity by sequestering essential monomers, matching the observed shift from protection to degeneration.

Testable Predictions

• Prediction 1: Acute knockdown of calbindin in young BFCNs will increase expression of parvalbumin/S100B and elevate rapid calcium buffering capacity.
• Prediction 2: This upregulation will correlate with decreased Hsp70 activity and a rise in insoluble, ubiquitinated protein fractions.
• Prediction 3: Enhancing ATP availability (e.g., via nicotinamide riboside supplementation) will attenuate aggregation despite calbindin loss.
• Prediction 4: Inhibiting the compensatory calcium‑binding proteins (using shRNA against parvalbumin) will reduce aggregate formation but exacerbate calcium dyshomeostasis and neuronal death.

Experimental Approach

1. Model: Use Cre‑dependent AAV‑shRNA to knock down calbindin specifically in BFCNs of adult mice (ChAT‑Cre line). Include control AAV‑scrambled.
2. Readouts:
   • Western blot/qPCR for calbindin, parvalbumin, S100B.
   • Fluorescent calcium‑indicator (GCaMP6f) imaging to quantify rapid buffering kinetics.
   • Sech‑based fractionation to separate soluble vs. insoluble protein pools; assess ubiquitin‑positive aggregates via filter‑trap assay.
   • Hsp70 ATPase activity assay.
   • Behavioral assays of attentional performance (5‑choice serial reaction time task).
3. Interventions:
   • ATP boost: nicotinamide riboside in drinking water.
   • Buffer block: AAV‑shRNA against parvalbumin.
4. Analysis: Compare aggregate load, soluble monomer levels, calcium transients, and cognitive scores across groups. Use two‑way ANOVA with post‑hoc Tukey.

Potential Outcomes

• Support: Calbindin loss → ↑ alternative CaBPs → ↑ ATP consumption → ↓ chaperone activity → ↑ insoluble aggregates; ATP rescue lowers aggregates without altering calcium buffering; blocking alternative CaBPs reduces aggregates but worsens calcium spikes and neuron loss.
• Refutation: Calbindin knockdown does not alter alternative CaBP expression or ATP levels, yet aggregates still rise; or ATP supplementation fails to affect aggregation despite improved energy status.

This hypothesis directly links calcium‑buffering compensation to proteostatic aggregation, offering a falsifiable framework to test whether aggregates represent a costly, ATP‑dependent containment strategy rather than mere debris.